STANÍK, Michal, Alexandr POPRACH, Michaela ZAPLETALOVÁ, Denisa KREJČÍ, Daniel MACIK, Ivo CAPAK, Jiří JARKOVSKÝ, Radek LAKOMY and Jan DOLEZEL. Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry. CLINICAL GENITOURINARY CANCER. DALLAS: CIG MEDIA GROUP, LP, 2019, vol. 17, No 4, p. "E759"-"E767", 9 pp. ISSN 1558-7673. Available from: https://dx.doi.org/10.1016/j.clgc.2019.04.007.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Comparison of Different Treatment Modalities Outcomes in Clinically Node-positive Bladder Cancer: Analysis of a Population-based Cancer Registry
Authors STANÍK, Michal (703 Slovakia, guarantor), Alexandr POPRACH (203 Czech Republic), Michaela ZAPLETALOVÁ (203 Czech Republic, belonging to the institution), Denisa KREJČÍ (203 Czech Republic, belonging to the institution), Daniel MACIK (203 Czech Republic), Ivo CAPAK (203 Czech Republic), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Radek LAKOMY (203 Czech Republic) and Jan DOLEZEL (203 Czech Republic).
Edition CLINICAL GENITOURINARY CANCER, DALLAS, CIG MEDIA GROUP, LP, 2019, 1558-7673.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.695
RIV identification code RIV/00216224:14110/19:00111954
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.clgc.2019.04.007
UT WoS 000476618100006
Keywords in English Chemotherapy; Combined modality therapy; Cystectomy; Lymphadenopathy; Urinary bladder neoplasms
Tags 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 3/1/2020 12:10.
Abstract
Recently, a few retrospective studies demonstrated a potential benefit of multimodal therapy in patients with clinically node-positive bladder cancer. We assessed the efficacy of different treatment modalities in 661 patients (cTanyN1-3M0) identified from the Czech National Cancer Registry. When compared with chemotherapy, combined treatment integrating cystectomy and perioperative chemotherapy reduced the risk of overall mortality by 21% and may lead to a long-term survival in one-quarter of patients. Introduction: Patients with clinically node-positive bladder cancer were historically considered to have uniformly poor prognosis and were frequently treated with palliative chemotherapy (CHT) only. Although retrospective data show that long-term survival with combined treatment (surgery + CHT) is possible in one-third of these patients, consensus on a treatment algorithm is still lacking. The aim of the study is to compare the efficacy of different treatment modalities based on data from a population-based cancer registry. Patients and Methods: The study comprises 661 patients identified from the Czech National Cancer Registry (1996-2015) with cTanyN1-3M0 bladder cancer; 195 were treated with CHT alone, 234 underwent radical cystectomy alone (RC), and 232 received a combination of RC and perioperative CHT (RC + CHT). Multivariate Cox proportional hazard regression analyses were used to evaluate the effectiveness of various treatments. Results: The 5-year OS for CHT alone, RC alone, and RC + CHT were 21.7% (95% confidence interval [CI], 15.4%-28.0%), 12.1% (95% CI, 7.4%-16.7%), and 25.4% (95% CI, 18.9%-31.9%), respectively (P < .001). The median survivals were 17, 10, and 23 months, respectively. In multivariate analysis, age > 60 years (hazard ratio, 1.29; 95% CI, 1.06-1.56; P = .011) and clinical stage cT3-4 (hazard ratio, 1.39; 95% CI, 1.12-1.71; P = .002) were negative predictors of survival. When compared with CHT, RC + CHT reduced the risk of overall mortality by 21% (P = .044). Conclusion: Approximately one-quarter of clinically node-positive patients may achieve long-term survival with combined treatment integrating RC and perioperative CHT. The overall survival of patients is significantly improved with a multimodal approach in comparison to CHT alone. (C) 2019 Elsevier Inc. All rights reserved.
PrintDisplayed: 31/5/2024 07:31